Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials

Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.